반응식
[NH:1]1[C:9]2[C:4](=[CH:5][CH:6]=[CH:7][CH:8]=2)[C:3]([C:10]([CH3:14])([CH3:13])[CH2:11][NH2:12])=[CH:2]1.I[CH3:16].[C:17]([O:21][C:22](N1C2C(=CC=CC=2)C(CC#N)=C1)=[O:23])(C)(C)[CH3:18]>>[CH2:17]([O:21][C:22]([CH:16]1[C:2]2[NH:1][C:9]3[C:4](=[CH:5][CH:6]=[CH:7][CH:8]=3)[C:3]=2[C:10]([CH3:14])([CH3:13])[CH2:11][NH:12]1)=[O:23])[CH3:18]참가 물질
4
실험 절차
4,4-Dimethyl-2,3,4,9-tetrahydro-1H-beta-carboline-1-carboxylic acid ethyl ester was prepared in a manner similar to that described in Example 66A by replacing tryptamine-HCl with 2-(1H-indol-3-yl)-2-methylpropylamine, which was synthesized using 2 equivalents of iodomethane during alkylation of (1-tert-butoxycarbonylindol-3-yl)acetonitrile as described in Example 32B; MS(ESI): 273(MH+).
후처리
- customwas synthesized
출처 및 근거
- ORD 기록
- ord-a971a8d9f3624726a4b729c4df358154
- 출처 데이터셋
- uspto-grants-2009_02
- 특허 번호
- US07485634B2
연결된 노트
불러오는 중…